Ascendiant analyst Edward Woo maintained a Buy rating on Lucid Diagnostics (LUCD – Research Report) on April 8 and set a price target of $10.00. The company’s shares closed yesterday at $1.45. According to TipRanks, Woo is an analyst with an average return of -2.5% and a 40.30% success rate. Woo covers the Healthcare sector, focusing on stocks such as BioSig Technologies, Vivos Therapeutics, and Biolase. Lucid Diagnostics has an analyst consensus of Strong Buy, with a price target consensus of $5.20, a 258.62% upside from current levels. In a report released on March 31, Needham also maintained a Buy rating on the stock with a $2.60 price target. See Insiders’ Hot Stocks on TipRanks >>  The company has a one-year high of $3.64  and a one-year low of $1.11. Currently, Lucid Diagnostics has an average volume of 112.4K.
		  TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma.  Read More on LUCD: Indices Commodities Currencies Stocks